This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based venture capital firm Avalon Ventures has boosted an Internet web site publisher known for its humorous, captioned pictures of cats and use of Internet memes, Cheezburger. Avalon's Levandov is also on the board and led the venture firm's investment in hot Internet social gaming firm Zynga.
and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.
Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK. Debuting in COI (which stands for “community of innovation”). Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.
According to a recent ScoreStream statement , San Diego’s Avalon Ventures, a longtime ScoreStream investor, led the round, and was joined by Sinclair Broadcasting, Verizon Ventures, and R/GA Ventures, the investment arm of the advertising agency R/GA. million in a Series A round that includes Intel Capital as an investor.
Pharmstandard International, the Luxembourg-based investment arm of the Russian pharmaceutical giant Pharmstandard (and a first-time investor in Avelas), led the round. It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp.,
I think they’re going to be very patient and pick their spots in terms of where they’re going to invest, and that’s going to put a lot of pressure on companies. If you map that backdrop of the overall investment environment against the backdrop where companies may. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Existing investors Avalon Ventures and Correlation Ventures joined in the round. The San Diego firms have invested $6 million since 2014, when Synthorx was founded , CEO Court Turner said yesterday.
Investment in experimental drugs for hearing loss, long an untapped field in the pharmaceutical industry, may be picking up, but drugs that actually help with these disorders remain elusive.
In the Bay Area, Roudi said about 180 companies pay Plug and Play an annual fee to get an inside track on incubating startups, and in some cases could be making investments in San Diego companies as well. billion under management. Cohen described Downtown Works as a “hyper-connector.”. Downtown Works Interior. It’s really cool.”.
Stockholders who had invested in the. Anaptys also sold 1 million more shares that it had initially planned. As has been the case for biotechs over the past year , insiders helped Anaptys get to the public market. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content